PDL Seeks Partner For Daclizumab In Asthma After Roche Backs Out
This article was originally published in The Pink Sheet Daily
Executive Summary
PDL BioPharma and Roche will continue to collaborate on daclizumab in transplant maintenance.
You may also be interested in...
Roche Backs Out Of Daclizumab Transplantation Deal With PDL
PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.
Roche Backs Out Of Daclizumab Transplantation Deal With PDL
PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.
PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
The biotech is “aggressively” seeking potential in-licensing opportunities and hopes to partner its heart failure agent ularitide in 2007.